Polaryx Therapeutics, Inc. Common stock, shares authorized (in shares) remained flat by 0.0% to $560.00M in Q1 2026 compared to the prior quarter.
An increase indicates that shareholders have approved a higher ceiling for potential future equity issuance, often for capital raises or stock-based compensation.
This represents the maximum number of common shares that a corporation is legally permitted to issue under its articles...
Standard corporate governance metric; companies often maintain a buffer between authorized and outstanding shares.
other_common_stock_shares_authorized| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $560.00M | $560.00M |
| QoQ Change | — | +0.0% |